PhRMA

JUNE 16, 2025

An alarming new IQVIA study found that Medicare Part D plans routinely deny access to prescribed medicines for patients with newly diagnosed chronic conditions. More than 70% of patients faced an initial immediate denial for their medicines in four of the five chronic therapeutic areas studied. Pharmacy benefit managers (PBMs) and plans increasingly use aggressive tactics to deny coverage, such as excluding physician-prescribed medicines from coverage and imposing harmful prior authorization and

157

157

PhRMA

JUNE 11, 2025

The United States is the epicenter of groundbreaking biopharmaceutical research, and maintaining this leadership requires investment in the future scientific workforce. This year marks the 60th year that the PhRMA Foundation has helped build and train this workforce. A 501(c)(3) nonprofit, the Foundation provides grants and fellowships to graduate students, postdoctoral trainees and new faculty members conducting novel research, setting the stage for tomorrow’s biomedical breakthroughs tha

100

100

PhRMA

JUNE 12, 2025

As lawmakers in Lansing debate health care legislation, new evidence reveals a staggering—and deeply troubling—reality: big, tax-exempt hospitals in the state are marking up the price of prescription medicines by nearly $10 billion a year. The federal 340B program is running unchecked with limited transparency and accountability, and comprehensive federal reform is needed to stop abuse of the program.

Hospitals 194

Hospitals 194

PhRMA

JUNE 2, 2025

Post-approval R&D is the continued investigation by biopharmaceutical companies, often through lengthy clinical trials, to find new uses and improvements for U.S. Food and Drug Administration (FDA)-approved medicines to better meet patient needs. Recently, there has been growing discussion among IP critics aimed at undermining the importance of post-approval R&D.

FDA 144

FDA 144

PhRMA

MAY 21, 2025

The Pharmaceutical Research and Manufacturers of America (PhRMA) today launched a new campaign to highlight why the United States pays higher drug prices than other countries and what policymakers can do to strike a better deal for American patients, taxpayers and employers. Entitled “Balance the Scales,” the ad is being released as there is an increased focus on international price differences.

Insurance 141

Insurance Hospitals 141

PhRMA

MAY 16, 2025

Government price setting policies like Most Favored Nation are a bad deal for American patients.

Hospitals 208

Hospitals 208

PhRMA

MAY 15, 2025

Government price setting policies like Most Favored Nation-pricing are bad for American patients, especially over the long term. These “foreign first pricing” schemes don’t guarantee lower costs. Instead, they take away dollars that could be invested in American manufacturing and undermine biopharma R&D. Most importantly, foreign reference pricing fails to address the real reasons Americans pay more for medicines than other countries: pharmacy benefit managers (PBMs), 340B

Hospitals 157

Hospitals 157

PhRMA

MAY 8, 2025

Despite what the insurance industry claims, prescription medicines are not the drivers of insurance premium costs.

Insurance 100

Insurance 100

PhRMA

MAY 7, 2025

PhRMA submitted comments to the U.S. Department of Commerce on its Section 232 investigation of pharmaceuticals and pharmaceutical ingredients imported to the United States.

130

130

PhRMA

MAY 5, 2025

PBM’s trade association, PCMA, recently launched a campaign to mask growing concerns over their role in the pharmaceutical supply chain and the rising cost of medicine for patients. The campaign is in response to elected officials nationwide joining the congressional momentum in calling for PBM reform. It’s time to rein in middlemen, like PBMs, who use medicines as a profit center and drive up the costs for patients, employers, and taxpayers.

157

157

PhRMA

MAY 1, 2025

Patients in the U.S. will soon be left with fewer new, affordable and convenient treatments, if Congress fails to fix a harmful provision in the Inflation Reduction Act (IRA) referred to as the “pill penalty.

176

176

PhRMA

MAY 1, 2025

The 340B hospital markup program continues to skyrocket every year. Yet there is little to no evidence that this immense growth is benefiting the uninsured and low-income patients that the program was designed to serve. If the money isn’t going to help patients, where is it going?

Hospitals 176

Hospitals 176

PhRMA

APRIL 29, 2025

America’s biopharmaceutical companies are committed to revitalizing American manufacturing, and they continue expanding their U.S. footprint. Supporting nearly five million jobs and more than 1,500 facilities across the U.S., we’re making investments that help develop new treatments and cures and contribute to America’s economy.

167

167

PhRMA

APRIL 29, 2025

Today, the Office of the U.S. Trade Representative (USTR) released the 2025 Special 301 Report. PhRMA welcomes USTR’s commitment to defending American innovation against harmful IP and market access practices in trading partners across the globe.

130

130

PhRMA

APRIL 28, 2025

As the United States confronts a resurgence of measles – a disease that was declared eliminated from the United States in 2000 through immunization – it’s a timely reminder of why vaccines remain one of the most powerful tools for preventing dangerous disease, protecting public health and reducing burden on the health care system.

Immunization 144

Immunization Vaccines 144

PhRMA

APRIL 28, 2025

April marks Medicaid Awareness Month –– a time to recognize the profound impact of the Medicaid program on the more than 80 million low-income Americans whom it serves, as well as the vital role the biopharmaceutical industry plays in ensuring these patients can access affordable medicines and treatments. Established in 1965 as part of President Lyndon B.

Insurance 144

Insurance 144

PhRMA

APRIL 25, 2025

Every April 26th, World Intellectual Property (IP) Day marks a time to celebrate the creativity and innovation that fuel our economy. In 2025, the spotlight is on music—a universal language that connects people, culture and moments. But what if you couldn’t hear it? What if the joy of music was locked away, not by choice, but by biology?

144

144

PhRMA

APRIL 10, 2025

These days, the same big health care conglomerate could own your PBM, insurer, pharmacy and even your doctor’s office. Middlemen now control what medicines you can get, what you pay at the pharmacy counter, what pharmacy you can you use and what hoops you must jump through to get the medicine your doctor prescribed.

Insurance 135

Insurance 135

PhRMA

APRIL 7, 2025

For more than four decades since the passage of the Hatch-Waxman Act, the U.S. generic drug market has provided patients with low-cost alternatives to brand-name medicines, saving the health care system billions while preserving incentives for biopharmaceutical innovation. Today, low-cost generics account for nine out of every 10 prescriptions dispensed in the United States and come with an average copay of about six dollars.

130

130

PhRMA

MARCH 28, 2025

Intellectual property (IP) protections are the foundation of U.S. global leadership in biopharmaceutical innovation. Patents and other IP protections over the past 25 years have fueled the delivery of over 750 new medicines for debilitating and devastating illnesses, such as cancer, heart disease and many rare diseases, by giving innovators the legal protection and confidence they need to take on the significant costs and risks associated with drug development.

FDA 196

FDA 196

PhRMA

MARCH 24, 2025

A new report by the Wall Street Journal reveals abuse of the 340B hospital markup program is getting worse as hospitals and middlemen find new ways to profit off the program.

Hospitals 242

Hospitals 242

PhRMA

MARCH 18, 2025

The United States leads the world in the research, development and manufacturing of innovative medicines. But the Inflation Reduction Act’s (IRA) “pill penalty” puts this leadership at risk by discouraging the development of treatments that often come in pill form like a tablet or capsule, also known as small molecule medicines. Under the IRA, these treatments can be price set years before other medicines, signaling to researchers that developing them is not worth the risk.

210

210

PhRMA

MARCH 17, 2025

Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program. As entities in the supply chain that don’t make medicine are increasingly using medicines to subsidize other parts of their business, patients and employers face increasing costs and barriers to accessing c

Insurance 263

Insurance Hospitals 263

PhRMA

MARCH 16, 2025

We live in a world where technology is playing an increasingly significant role in our daily lives. In the biopharmaceutical industry, using artificial intelligence (AI) as a tool can help improve efficiency, discover new cures and treatments and enhance clinical trials. The American biopharmaceutical sector is built on a strong foundation of intellectual property protections and a flexible regulatory framework, both of which foster life-saving innovation in the United States.

144

144

PhRMA

MARCH 12, 2025

Health care practitioners (HCPs), and patients too, are sounding the alarm on unnecessary barriers in the system that can negatively impact patients’ access to quality care according to a new survey of HCPs and patients. Specifically, HCPs raised concerns over how pharmacy benefit managers (PBMs) and insurers inappropriately use utilization management tools, like prior authorization, to deny or delay care, ultimately harming the patient and impacting patient access to care.

Patient Care 298

Patient Care Insurance 298

PhRMA

MARCH 12, 2025

President Trump has made it clear that his administration is focused on supporting American workers and manufacturers, while tackling unfair and non-reciprocal trade practices by foreign governments. PhRMA and its members share these goals. To help inform the administration’s America First Trade Policy, PhRMA submitted comments to the U.S. Trade Representative (USTR) highlighting policies abroad that harm American biopharmaceutical innovation and leadership.

100

100

PhRMA

MARCH 10, 2025

Measles was declared eliminated in the United States in 2000, thanks to widespread vaccination with the MMR vaccine. Unfortunately, in recent weeks, there has been an alarming increase in measles cases across the country – from Texas and New Mexico to New York and Rhode Island and the first reported death in a decade.

Vaccines 144

Vaccines 144

PhRMA

MARCH 6, 2025

Lawmakers on both sides of the aisle are renewing a multi-year effort to crack down on drug middlemen, known as pharmacy benefit managers (PBMs). These middlemen control what patients pay at the pharmacy counter, where they can get their medicine, what medicines they can get and what hoops they must jump through. The effort in Congress reflects mounting pressure to hold PBMs accountable and help lower patients’ out-of-pocket costs.

176

176

PhRMA

MARCH 5, 2025

It’s well understood that without clinical trials there wouldn’t be all the groundbreaking innovative, life-saving drugs that patients rely on, but less understood is their significant economic impact across the United States. New research by TEConomy Partners, in concert with PhRMA, quantifies the impact of clinical trials across all 50 states, Puerto Rico and the District of Columbia.

167

167

PhRMA

MARCH 4, 2025

A tranche of recent reports reveal that the 340B hospital markup program is costing states and the federal government hundreds of millions of dollars in lost tax revenue.

Hospitals 134

Hospitals 134

PhRMA

FEBRUARY 27, 2025

Today, we join patients and their loved ones from across the country and around the world in observance of Rare Disease Day. No matter how many patients may be impacted, each disease is far from rare for those who live with it every day. That’s why America’s biopharmaceutical research companies are working around the clock to develop new treatments that can provide hope and relief for those living with rare diseases.

176

176

PhRMA

FEBRUARY 20, 2025

This week, PhRMA released a new policy agenda with key facts and figures outlining America’s challenge for continued leadership in biopharmaceutical innovation and PhRMA’s proactive solutions that underpin our advocacy. Our inefficient system costs Americans more than necessary and gets in the way of our ability to prioritize keeping people healthy.

130

130

PhRMA

FEBRUARY 20, 2025

The innovation that happens every day in America’s biopharmaceutical companies prevents disease, transforms lives and creates a healthier America. While we know there are still serious illnesses that remain to be conquered, the progress we’ve made in the past 25 years has changed the lives of countless patients and their families.

111

111

PhRMA

FEBRUARY 19, 2025

I first joined the health care industry in the early 2000s. At that time, the Human Genome Project had yet to be completed. Concepts like immunotherapy, gene therapy and CAR-T were barely an idea. And there were few treatments for diseases like Hepatitis C, melanoma and cystic fibrosis.

100

100

PhRMA

FEBRUARY 19, 2025

Earlier this year, the American Cancer Society (ACS) released its annual report on cancer facts and trends – Cancer Statistics 2025. Notably, this new report found that the cancer mortality rate declined in the U.S. by an astounding 34% since peaking in 1991, averting 4.5 million deaths.

200

200

PhRMA

FEBRUARY 19, 2025

It’s well understood that without clinical trials there wouldn’t be all of the groundbreaking innovative, life-saving drugs that patients rely on, but less understood is their significant economic impact across the United States. New research by TEConomy Partners, in concert with PhRMA, quantifies the impact of clinical trials across all 50 states, Puerto Rico and the District of Columbia.

130

130

PhRMA

JANUARY 7, 2025

Half of every dollar spent on brand medicines goes to entities that play no role in the research, development, or manufacturing of those medicines, according to a new analysis by Berkeley Research Group (BRG).

100

100